What was tested
Maria Rajan, Ouyang, Idrees, Kujan, and Fawzy at UWA Dental School report in Clinical Oral Investigations (volume 29, article 528, published 24 October 2025) a dose-finding study of tideglusib combined with low-intensity focused ultrasound (LIFU) in human dental pulp stem cells (DPSCs), run in both standard and LPS-induced inflammatory conditions (Maria Rajan et al. 2025, DOI 10.1007/s00784-025-06616-7). Tideglusib is the GSK-3 antagonist from the Neves et al. (2017) mouse reparative-dentine work, so the study sits in the pulp-dentin repair program (/programs/pulp-dentin-repair/). Everything reported is in vitro; there is no animal or human data.
Doses and readouts
The authors exposed DPSCs to tideglusib at 100, 250, and 500 nM and to LIFU at 250 kHz, 2.5 W and 5 W, for 60 s and 120 s, then selected 100 nM tideglusib and the 5 W, 120 s ultrasound condition as optimal (same source, Methods). Proliferation was measured with an acid phosphatase assay and confocal microscopy; odontogenic differentiation with Alizarin red staining, a wound-healing assay, and qRT-PCR for RUNX2, ALPL, BMP2, DMP1, the Wnt readout AXIN2, and the apoptosis genes CASP3 and BCL2L1.
What the combination did
At the selected dose (5 W, 120 s, 100 nM), the combination significantly enhanced (p < 0.05) proliferation, mineralization, and wound closure in both the standard DPSC group and the LPS-inflamed group (same source, Results). qRT-PCR showed upregulation of the odontogenic and Wnt markers. In the LPS-inflamed cells specifically, CASP3 was downregulated and BCL2L1 upregulated, which the authors read as improved survival under inflammatory stress.
Why it matters for the route
This is the same UWA program we covered on 24 August 2026, when the group’s tideglusib-loaded hyaluronic acid hydrogel paper left the acoustic dose unspecified. The present study, published earlier but newly surfaced in our indexes, supplies those parameters: 250 kHz at 2.5 to 5 W for 60 to 120 s. It also extends the group’s earlier tideglusib-plus-LIFU findings from healthy cells to an LPS inflammation model, the condition that matters clinically, since candidate teeth for biological pulp repair are usually inflamed. AXIN2 upregulation is consistent with the canonical Wnt mechanism the route is built on.
What it does and does not show
This is a cultured-cell study, not a pulp-capping model and not a trial. It shows a synergistic in vitro effect at defined drug and ultrasound doses, including under LPS stress, and it names the LIFU parameters the hydrogel paper omitted. It does not show organized reparative dentin, in vivo dosing, or comparison with standard capping materials such as mineral trioxide aggregate. An inflammatory in vitro model is also a coarse stand-in for carious human pulp, and the abstract reports no effect sizes beyond significance.
Where we differ from the coverage
We found no press or popular coverage of this paper to differ from. Any framing that presents ultrasound plus tideglusib as an available dental therapy overstates an in vitro result.
Provenance: grounded in the publisher page and abstract for DOI 10.1007/s00784-025-06616-7 (Clinical Oral Investigations); the full text is paywalled and was not read, so no figures, sample sizes, or statistics beyond those in the abstract are claimed. Method and sourcing standard at /method/.